Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
341 Leser
Artikel bewerten:
(1)

Sitero, LLC: Sitero Acquires Clario's eClinical Technology Suite to Enhance Clinical Trial Delivery

MIAMI, Aug. 1, 2023 /PRNewswire/ -- Sitero, a next-generation, site-focused CRO and a leading provider of clinical trial solutions, is thrilled to announce its recent acquisition of an advanced technology suite designed to manage the end-to-end clinical trial lifecycle. This strategic acquisition underscores Sitero's commitment to staying at the forefront of innovation and providing its clients with unparalleled technology-enabled support and services.

Sitero logo

The newly acquired eClinical technology suite will be integrated with Sitero's existing Mentor platform with plans to invest heavily in AI to further streamline the clinical trial process from start to finish. Equipped with state-of-the-art features and functionalities, this combined suite offers an array of tools designed to enhance efficiency, accuracy and quality of data across the site, CRO and Sponsor lifecycle of clinical trials.

Key components of the technology platform include:

  • Electronic Data Capture (EDC) and System: This advanced EDC software enables real-time data collection, management, and analysis, improving accuracy and reducing administrative burdens. The EDC system ensures seamless data integration and compliance with regulatory standards.
  • Randomization and Trial Supply Management (RTSM): This purpose-built, end-to-end, configurable RTSM solution is easy to integrate, can support rapid study start-up, and provides the functionality required to meet the level of complexity of all types of clinical trials.
  • Clinical Trial Management System (CTMS): The CTMS platform provides access to a full-featured solution with rapid deployment capabilities, while minimizing the risk associated with a significant upfront investment.
  • eTMF: The eTMF clinical trial software can get up and running quickly and efficiently. It maximizes value, minimizes headaches, and meets all regulatory requirements, from support for the most recent DIA Reference Model to 21 CFR Part 11 compliance to a complete audit trail.
  • eConsent: The eConsent system is built from the ground up for the way clinical trials are run today by turning a regulatory checkbox into a powerful tool for engagement that can accelerate study completion and improve patient experience.
  • Site and Patient Payments: This technology-driven software offers the industry's only purpose-built, fully integrated, and end-to-end clinical trial financial software solution that provides fast, accurate insight from forecast to final payment.

"This acquisition supports our mission to advance clinical research with a next-generation, technology-enabled delivery model. We are excited about the opportunity this provides Sitero to achieve our near- and long-term goals of changing how trials are run through technology enabled solutions," said Sankesh Abbhi, CEO at Sitero. "This acquisition expands our clinical offerings with a flexible and user-friendly suite of clinical technology solutions that we expect to further strengthen the foundation of our Mentor technology platform."

The Clario eClinical product suite will be rebranded and integrated into the established Sitero Mentor platform. Sitero Mentor will continue to support the existing Clario customer base while further developing innovative Clinical solutions for new customers as well.

Commenting on the sale, Chris Fikry, CEO of Clario said "Our clinical trial solutions business provides important support and services for our sponsors looking for an end-to-end solution for their clinical trial. Following a strategic review of the business, Clario determined the best path forward is a sale to Sitero. Sitero will be able to provide the strong strategic support the business needs to grow and Clario looks forward to maintaining a partnership with the business going forward."

For more information about Sitero and its comprehensive suite of clinical trial solutions, please visit www.sitero.com or contact us at info@sitero.com

Logo - https://mma.prnewswire.com/media/2013928/Sitero_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/sitero-acquires-clarios-eclinical-technology-suite-to-enhance-clinical-trial-delivery-301889743.html

© 2023 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.